{
    "2019-05-05": [
        [
            {
                "time": "2019-04-30",
                "original_text": "【西南医药】医药行业2018年年报及2019年一季报总结：行业分化明显，疫苗、CRO和药店等表现抢眼",
                "features": {
                    "keywords": [
                        "医药行业",
                        "年报",
                        "一季报",
                        "行业分化",
                        "疫苗",
                        "CRO",
                        "药店"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "疫苗",
                        "CRO",
                        "药店"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-05-10",
                "original_text": "板块分化后的投资策略 ——兴证医药2019年5月投资月报",
                "features": {
                    "keywords": [
                        "板块分化",
                        "投资策略",
                        "兴证医药",
                        "投资月报"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-05-15",
                "original_text": "【招商医药】医药生物行业18年年报及19年一季报回顾--医药整体业绩探底，内部分化明显",
                "features": {
                    "keywords": [
                        "医药生物",
                        "年报",
                        "一季报",
                        "业绩探底",
                        "内部分化"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-05-20",
                "original_text": "【国盛医药张金洋团队】年报季报验证医药从野蛮扩张到结构优化，继续推荐医药流通",
                "features": {
                    "keywords": [
                        "医药",
                        "年报",
                        "季报",
                        "野蛮扩张",
                        "结构优化",
                        "医药流通"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "医药流通"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}